Luna LifeSci Advisors
Luna LifeSci Advisors consults across the NAMs ecosystem, helping MPS developers grow and scale novel platforms, and guiding pharma and CROs to evaluate, adopt, and integrate MPS technologies into preclinical workflows. Our 25+ years of expertise spans strategy, technology development, platform validation, workflow integration, regulatory alignment, fundraising, company building, and commercial execution.
CanChip GmbH
We are a commercial provider of a microphysiological system either as a product or service.
TheWell Bioscience
TheWell Bioscience provides xeno-free, 3D cell culture solutions, empowering research in organoids, regenerative medicine, and drug discovery.
VoxCell
VoxCell empowers scientists and drug developers to study drug behavior with unprecedented physiological relevance. With vascular complexity at the core of our innovation, VoxCell delivers human-like models that accelerate therapeutic discovery and bridge the gap between preclinical and clinical phases. Committed to innovation and excellence, VoxCell continues to expand its impact on a global scale.
Bioprinting Laboratories
Bioprinting Labs’ pillar/perfusion plates enable robust and reproducible organoid culture and in situ analysis. Our products streamline organoid-based assays by facilitating miniature organoid culture and enhancing organoid maturity through dynamic culture in the pillar/perfusion plates.
Exir Bio
Exir Bio’s goal is to accelerate drug discovery, efficacy, and safety assessments by combining nonhuman primate (NHP) in vitro / in vivo models,
replacing, reducing, and refining (3R’s) the use of NHPs – necessary due to the global shortage of NHPs and in accordance with US Modernization Act
2.0.
Exir Bio has access to ~20,000 NHP’s / 8 species across several colonies in the US, all with known origin and bred in captivity per FDA and European
Union requirements.
STEMCELL Technologies
We are the world-leading provider of reagents and services for generating organoid and stem cell-derived models of healthy and diseased human tissues.
AlveoliX
AlveoliX has developed an adaptable organ-on-chip platform that enables the modelling of all tissue barriers, including the associated mechanical forces. Our technology is suitable for a wide range of applications including drug safety and efficacy testing, inhalation toxicology assessment and answering fundamental research questions. Our technology can be implemented in your laboratory, or utilised through our CRO services
SynVivo, Inc.
Organ-on-Chip models from SynVivo recreate complex microvasculature including scale, morphology, hemodynamic shear stress, and cellular interactions in a perfused microfluidic chip environment. Validated models include Air Liquid Interface for Lung, Blood-Brain Barrier, Tumor, DIVI, Inflammation.